Medtronic Q4 EPS of $1.55, 78% Cardiac Ablation Growth Sparks 5.5% Rally
MDT•Medtronic reported Q4 revenue of $9.8 billion and adjusted EPS of $1.55, beating expectations and driving a 5.46% stock gain. Its Cardiac Ablation Solutions business delivered 78% global and 124% U.S. revenue growth, setting up a projected $2 billion segment and forecasting 6.75%-7.25% organic revenue growth in FY27.
1. Q4 Financial Results
Medtronic posted quarterly revenue of $9.8 billion and adjusted EPS of $1.55, surpassing analyst estimates and triggering a 5.46% share price increase. The strong top-line performance marks the company's highest revenue growth in a decade.
2. Cardiac Ablation Solutions Performance
The Cardiac Ablation Solutions segment saw 78% revenue growth globally and 124% in the United States, securing eight points of U.S. market share and positioning the unit to generate approximately $2 billion in revenue.
3. Fiscal 2027 Outlook and Guidance
Management forecasts organic revenue growth of 6.75% to 7.25% for fiscal 2027 while providing cautious full-year EPS guidance of $5.90 to $6.00 due to tariff pressures and acquisition costs. The company continues investing in innovation, including ICE catheter technology and the MiniMed IPO.
